| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer
|
Bonnetain, F.
|
|
|
17 |
5 |
p. 827-834
|
artikel
|
| 2 |
A good death for cancer patients: still a dream?
|
Aitini, E.
|
|
|
17 |
5 |
p. 733-734
|
artikel
|
| 3 |
Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients
|
Vincenzi, B.
|
|
|
17 |
5 |
p. 835-841
|
artikel
|
| 4 |
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
|
Dowsett, M.
|
|
|
17 |
5 |
p. 818-826
|
artikel
|
| 5 |
Bortezomib (VELCADE®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits
|
Yang, C.H.
|
|
|
17 |
5 |
p. 813-817
|
artikel
|
| 6 |
Breast cancer vaccines: a clinical reality or fairy tale?
|
Curigliano, G.
|
|
|
17 |
5 |
p. 750-762
|
artikel
|
| 7 |
Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa
|
Ferreri, A.J.M.
|
|
|
17 |
5 |
p. 769-772
|
artikel
|
| 8 |
Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis
|
Das, P.
|
|
|
17 |
5 |
p. 785-793
|
artikel
|
| 9 |
Cost–opportunity analysis in clinical oncology: from the ‘wild far-west’ to a correct integration of the disciplines, avoiding the ‘war of the worlds’
|
Tassinari, D.
|
|
|
17 |
5 |
p. 876-877
|
artikel
|
| 10 |
Diagnosis and prognosis disclosure among cancer patients. Results from an Italian mortality follow-back survey
|
Costantini, M.
|
|
|
17 |
5 |
p. 853-859
|
artikel
|
| 11 |
Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment
|
Glaus, A.
|
|
|
17 |
5 |
p. 801-806
|
artikel
|
| 12 |
18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading
|
Wöhrer, S.
|
|
|
17 |
5 |
p. 780-784
|
artikel
|
| 13 |
Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study
|
Iacopetta, B.
|
|
|
17 |
5 |
p. 842-847
|
artikel
|
| 14 |
Home treatment for intensive hematological therapies: who will benefit?
|
Schouten, H.C.
|
|
|
17 |
5 |
p. 731-732
|
artikel
|
| 15 |
Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring
|
Crivellari, D.
|
|
|
17 |
5 |
p. 807-812
|
artikel
|
| 16 |
in this issue
|
|
|
|
17 |
5 |
p. 729
|
artikel
|
| 17 |
NK/T-cell lymphomas ‘nasal type’: an Italian multicentric retrospective survey
|
Pagano, L.
|
|
|
17 |
5 |
p. 794-800
|
artikel
|
| 18 |
Novel formulations of taxanes: a review. Old wine in a new bottle?
|
Hennenfent, K.L.
|
|
|
17 |
5 |
p. 735-749
|
artikel
|
| 19 |
Occupational asbestos exposure: how to deal with suspected mesothelioma cases—the Dutch approach
|
Baas, P.
|
|
|
17 |
5 |
p. 848-852
|
artikel
|
| 20 |
Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer
|
Choueiri, T.K.
|
|
|
17 |
5 |
p. 860-865
|
artikel
|
| 21 |
Reply to the article “A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis”, by J. Norum et al. (Ann Oncol 2005; 16: 909–914)
|
Bonneterre, M.E.
|
|
|
17 |
5 |
p. 875
|
artikel
|
| 22 |
Reply to the Letter to the Editor, by J. Bonneterre and M. E. Bonneterre (Ann Oncol 2006; 17: 875)
|
Norum, Jan
|
|
|
17 |
5 |
p. 875-876
|
artikel
|
| 23 |
Reply to the Letter to the Editor on ‘Cost–opportunity analysis in clinical oncology: from the “wild far-west” to a correct integration of the disciplines, avoiding the “war of the worlds”’, by D. Tassinari et al. (Ann Oncol 2006; 17: 877)
|
Colleoni, M.
|
|
|
17 |
5 |
p. 878
|
artikel
|
| 24 |
Reply to the Letter to the Editor on ‘Cost-opportunity analysis in clinical oncology: from the “wild far-west” to a correct integration of the disciplines, avoiding the “war of the worlds”’, by D. Tassinari et al. (Ann Oncol 2006; 17: 876)
|
Bocci, G.
|
|
|
17 |
5 |
p. 877-878
|
artikel
|
| 25 |
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
|
Richly, H.
|
|
|
17 |
5 |
p. 866-873
|
artikel
|
| 26 |
Shifting to outpatient management of acute myeloid leukemia: a prospective experience
|
Savoie, M.L.
|
|
|
17 |
5 |
p. 763-768
|
artikel
|
| 27 |
St Gallen guidelines: aromatase inhibitors recommended by name for adjuvant therapy
|
Buzdar, A.U.
|
|
|
17 |
5 |
p. 878-879
|
artikel
|
| 28 |
Table of Contents
|
|
|
|
17 |
5 |
p. i-ii
|
artikel
|
| 29 |
The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours
|
Last, K.
|
|
|
17 |
5 |
p. 773-779
|
artikel
|
Tijdschrift beschrijving